StockMarketWire.com - Silence Therapeutics said it had appointed Giles Campion as its new head of R&D and chief medical officer.

Campion had previously served as chief medical officer at Prosensa and had also held senior R&D roles at Novartis.

'He has an outstanding track record of leading scientific development and advancing oligonucleotide-based medicines and is therefore ideally qualified to accelerate the development of our current and future pipeline,' chief executive David Horn Solomon said.

The appointment would take effect on 1 June.




Story provided by StockMarketWire.com